source
- Novartis MS drug remibrutinib cuts relapse rates by about a third in Phase 3 trialsData presented at an MS conference in Toronto showed that Novartis' experimental therapy, remibrutinib, reduced the annualized relapse rate in relapsing‑remitting multiple sclerosis by roughly 35%…
- New Medicare rules could restrict pain medication access for many patients, doctor warnsA recent Medicare policy proposal would tighten coverage criteria for certain pain‑relief treatments, potentially limiting their availability to patients who rely on them for daily functioning. Ph…